Table 1.
Measured parameters during each of the interventions
| n | AoP, mmHg | HR, min−1 | DP Work | CBF LV, ml·g−1·min−1 | CBF RV, ml·g−1·min−1 | CBF/CO, % | MRO2 LV, μl O2·g−1·min−1 | RDLV, % | RDRV, % | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1 control 1 | 4 | Mean ± SD | 97 ± 12 | 79 ± 12 | 9.4 ± 0.4 | 0.54 ± 0.14 | 0.37 ± 0.12 | 3.1 ± 0.8 | 45 ± 6 | 25.4 ± 3.4 | 28.4 ± 9.2 |
| Range | 21–32 | 20–42 | |||||||||
| LM LoMetab | 3 | Mean ± SD | 131 ± 22 | 173 ± 58 | 26.2 ± 8.5 | 1.56 ± 0.56 | 1.18 ± 0.33 | 5.3 ± 1.4 | 144 ± 19 | 22.9 ± 1.4 | 28.0 ± 13.1 |
| Range | 22–24 | 25–40 | |||||||||
| HiMetab | 4 | Mean ± SD | 171 ± 22 | 200 ± 38 | 36.5 ± 8.6 | 2.41 ± 0.92 | 1.61 ± 0.66 | 7.0 ± 1.2 | 206 ± 49 | 24.5 ± 3.2 | 28.8 ± 5.3 |
| Range | 21–28 | 24–37 | |||||||||
| HM + Ado | 4 | Mean ± SD | 107 ± 8 | 185 ± 22 | 25.0 ± 2.4 | 4.20 ± 0.91 | 3.70 ± 0.68 | 11.9 ± 2.4 | 179 ± 75 | 20.0 ± 5.4 | 15.9 ± 1.8 |
| HiMet Vasod | Range | 13–26 | 15–20 | ||||||||
| C2 | 3 | Mean ± SD | 101 ± 5 | 181 ± 10 | 20.9 ± 1.6 | 0.98 ± 0.16 | 0.64 ± 0.25 | 4.5 ± 0.6 | 71 ± 16 | 25.6 ± 4.2 | 27.3 ± 6.9 |
| Control 2 | Range | 21–30 | 22–36 | ||||||||
| Ado Vasodi | 1 | Mean | 102 | 147 | 19.7 | 4.17 | 3.23 | 12.6 | 110 | 20.4 | 18.1 |
Values are means ± SD and ranges; n, no. of experiments.
AoP, mean aortic pressure; HR, heart rate; DP, “double product” work = heart rate times systolic aortic pressure; CBF, coronary blood flow to left ventricle (LV) and right ventricle (RV); CBF/CO, the percentage of total LV + RV coronary blood flow (ml/min)/cardiac output also in ml/min; MRO2, LV myocardial oxygen consumption; RDLV and RDRV, %relative dispersions of the distribution of regional blood flow to the left and right ventricles, respectively; C1, initial control; LM, low-level catecholamines; HM, high-level catecholamines; HM + Ado, high-level catecholamines + adenosine; C2, final control; Ado, adenosine alone was infused following the initial control in heart 4.